Merck Positions MK-8591 As Backbone For HIV Treatment And Prophylaxis

 
• By Joseph Haas
Pills for Pre-Exposure Prophylaxis (PrEP) to prevent HIV with PrEP text engraved
Merck hopes to follow Gilead as the second company into the HIV PrEP space

More from Clinical Trials

More from R&D